Part 2 of our animated video series features
@PsyPANglobal
PsyPAN improves participant safety in clinical trials by building best practices across the psychedelic sector
"By connecting together in the outer world, we can transform people's inner worlds" https://t.co/2r4uvLNCJi
PsiloNautica supports charities operating in the psychedelic space to flourish with our unique animation style
Please see part one of our four-part charity series that we will be releasing in the coming months
Part 1 - @HeroicHeartsUK / @WeHeroicHearts
https://t.co/CjJl4CDUaG
We are beginning to recruit individuals with #depression for our #ketamine brain imaging study, taking place in South East London @KingsCRF. Please see advertisement below and share widely. If interested please contact the study team: [email protected].
The work of the @anyoneschild campaign may well have the highest potential impact of any of the drug reform projects in the UK. Even if you're not looking for a job, do check out the work they do!
🚨WE ARE RECRUITING!🚨
We are looking for a Project Coordinator for our @AnyonesChild campaign.
Come & work with our brilliant team, & incredible families to further raise the campaign’s profile and expand our network of activists.
Deadline 10th July
https://t.co/6BF7gYvtVF
📚Friday Afternoon reads...
This week @psilonautica & @Drug_Science published a major poll revealing a majority of support for the rescheduling of psilocybin.
Here's Psilonautica Research Director @eddietalksdrugs on what this means for reform
https://t.co/pBsGyGWyTj
Last week @psilonautica & @Drug_Science published a landmark Yougov poll that revealed over half of the population back the rescheduling of psilocybin.
Here's Research Director @eddietalksdrugs
on what this means for psilocybin 👇👇
https://t.co/pBsGyGWyTj
Nationwide public support for #psilocybinaccessrights - read a detailed breakdown on the compassion of the #British public - now it's just our outdated and unscientific #drug policies standing in the way: https://t.co/BliJAhdfrN @psilonautica@Drug_Science
Hello, world!
Our first public-facing project, a collaboration with @Drug_Science, is now live! We're pleased to report that the UK wants the Home Office to #ReschedulePsilocybin!
Full results, and report by our research director @eddietalksdrugs, here:
https://t.co/7ztrIy9VHG
"Gül Dolen has lit up the science of MDMA: She used it to get octopuses to snuggle. She used it to teach old mice new tricks. Now Gül may be on the verge of some of the biggest discoveries in psychedelic history, testing new treatments for autism, stroke, and language deficits"
Gül Dölen “is a deep and broad thinker who challenges the limits of how we may conceptualize the mechanisms by which these drugs work.”
- Fred Barrett
https://t.co/rMsZakuFJ8
@TheDailyShroom That's a tight deadline! We'd need seismic regulatory shifts. I can plausibly see it happening by 2033, with cannabis bridging the gap until then.
If we can provide an effective antidepressant to people who don't *want* to trip, that's a positive thing.
Still, my money is on tripless psychedelic treatment not having a long-term future.
We shall see!
This may well explain what we know about microdosing so far - if it generates a (non-placebo) boost to mood or perceived wellbeing, all the other (cognition/creativity) bumps subjectively reported could be due to more positive self-assessment.
Research from Australia suggests #microdosing#LSD could be as beneficial as other wellness activities, such as #yoga.
Find out more about microdosing here: https://t.co/BTxSB34OIf 🧘
@stephenjbright@vincepsy
https://t.co/9qZunlaNsb
"The world's foremost psychedelic researcher is joining the world's foremost translational neuroscience lab at one of the world's foremost biomedical research institutions"
Kudos to @RCarhartHarris on his upcoming move, and shiny new professorship @UCSF!
https://t.co/rrFZxt6v0N